Advice

Recommended for restricted use within NHS Scotland.

RECOMMENDATION.

Valganciclovir offers a convenient oral alternative to ganciclovir. It is currently only licensed for the management of CMV retinitis in AIDS patients. Its use should be under the overall supervision of an expert ophthalmologist and a physician experienced in the management of HIV / AIDS patients.

Download detailed advice19KB (PDF)

Download

Medicine details

Medicine name:
Valganciclovir (Valcyte)
SMC ID:
21/02
Indication:
Induction and maintenance treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS).
Pharmaceutical company
Roche
BNF chapter
Infections
Submission type
Full
Status
Restricted
Date advice published
06 December 2002